Altimmune, Inc. (ALT)
2.585
-0.02
(-0.96%)
USD |
NASDAQ |
Jun 11, 16:00
2.60
+0.02
(+0.58%)
After-Hours: 20:00
Altimmune Net Income (Quarterly) : -22.56M for March 31, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | -22.56M |
| December 31, 2025 | -27.36M |
| September 30, 2025 | -19.01M |
| June 30, 2025 | -22.15M |
| March 31, 2025 | -19.58M |
| December 31, 2024 | -23.18M |
| September 30, 2024 | -22.84M |
| June 30, 2024 | -24.64M |
| March 31, 2024 | -24.39M |
| December 31, 2023 | -31.64M |
| September 30, 2023 | -20.67M |
| June 30, 2023 | -16.06M |
| March 31, 2023 | -20.07M |
| December 31, 2022 | -21.66M |
| September 30, 2022 | -23.52M |
| June 30, 2022 | -20.11M |
| March 31, 2022 | -19.43M |
| December 31, 2021 | -23.89M |
| September 30, 2021 | -33.51M |
| June 30, 2021 | -24.83M |
| March 31, 2021 | -14.86M |
| December 31, 2020 | -10.62M |
| September 30, 2020 | -17.77M |
| June 30, 2020 | -16.77M |
| March 31, 2020 | -3.886M |
| Date | Value |
|---|---|
| December 31, 2019 | -4.097M |
| September 30, 2019 | -10.94M |
| June 30, 2019 | -3.387M |
| March 31, 2019 | -2.097M |
| December 31, 2018 | -24.51M |
| September 30, 2018 | -2.351M |
| June 30, 2018 | -9.139M |
| March 31, 2018 | -3.174M |
| December 31, 2017 | -8.831M |
| September 30, 2017 | -29.91M |
| June 30, 2017 | -3.155M |
| March 31, 2017 | -4.579M |
| December 31, 2016 | -3.062M |
| September 30, 2016 | -4.795M |
| June 30, 2016 | -1.704M |
| March 31, 2016 | -1.227M |
| December 31, 2015 | -1.238M |
| September 30, 2015 | -1.325M |
| June 30, 2015 | -2.341M |
| March 31, 2015 | 1.463M |
| December 31, 2014 | -2.629M |
| September 30, 2014 | -4.628M |
| June 30, 2014 | -0.4391M |
| March 31, 2014 | -2.258M |
| December 31, 2013 | -4.425M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Agenus, Inc. | 39.21M |
| Amgen, Inc. | 1.819B |
| Halozyme Therapeutics, Inc. | 150.05M |
| Protalix Biotherapeutics, Inc. | 18.32M |
| Humacyte, Inc. | -17.62M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 22.56M |
| EPS Diluted (Quarterly) | -0.1813 |
| Enterprise Value | 44.14M |
| Earnings Yield | -36.27% |
| Normalized Earnings Yield | -36.27 |